Pharmaceutical giants AstraZeneca and Bristol Myers Squibb are reportedly on the cusp of a massive $400 billion merger, a deal that could shake up the industry and leave investors eagerly anticipating the details. However, concerns are mounting among shareholders about the potential risks associated with the tie-up, including the looming patent cliff that could lead to a sharp decline in revenue. As the companies' combined portfolio of blockbuster medications faces patent expirations, investors are questioning how the merged entity will adapt to the changing market landscape and maintain its market share. Meanwhile, antitrust regulators will also be keeping a close eye on the deal, scrutinizing its potential impact on competition and pricing in the pharmaceutical sector.
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
